cyproterone acetate has been researched along with Blood Loss, Surgical in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abo-El-Enen, M; El-Gamal, OM; El-Hitham, AA; El-Rasheedy, M; Elbendary, MA; Gameel, TA; Ghoneem, A; Sabaa, M; Soliman, MG | 1 |
| Abrahamsson, PA; Ahlgren, G; Aus, G; Hugosson, J; Lundberg, S; Pedersen, K; Schain, M; Schelin, S | 1 |
2 trial(s) available for cyproterone acetate and Blood Loss, Surgical
| Article | Year |
|---|---|
Perioperative use of cyproterone acetate with transurethral resection of large prostate: preliminary results.
Topics: Androgen Antagonists; Blood Loss, Surgical; Cyproterone Acetate; Humans; Male; Middle Aged; Organ Size; Perioperative Care; Postoperative Complications; Postoperative Hemorrhage; Prostate; Prostatic Hyperplasia; Transurethral Resection of Prostate | 2015 |
The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neo-adjuvant hormone treatment.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Blood Loss, Surgical; Chemotherapy, Adjuvant; Cyproterone Acetate; Humans; Male; Neoplasm Staging; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Testosterone; Time Factors; Triptorelin Pamoate | 1996 |